Скачать или смотреть Retatrutide: Why Eli Lilly's Triple Agonist is a Game Changer

Unlock the future of metabolic medicine! Dive deep into Eli Lilly’s groundbreaking investigational triple agonist, Retatrutide, and its potential to revolutionize obesity and diabetes research.

The global peptide therapeutics market is booming, projected to hit $87.21 billion by 2035. In this video, Sonia Rao dissects Retatrutide, a novel polypeptide from Eli Lilly, making waves with its unique mechanism of action. Learn how this triple agonist simultaneously targets GIP, GLP-1, and glucagon receptors to modulate appetite, energy expenditure, and glucose homeostasis. We'll explore compelling Phase 2 trial data, including an average 24.2% weight reduction in participants, surpassing current GLP-1 agonists. Understand its safety profile, consistent with incretin-based therapies, and its rapid progression through Phase 3 trials (SYNERGY-1, SURMOUNT, SUMMIT). This analysis is crucial for any serious research team tracking advancements in anti-obesity and anti-diabetic peptides. Stay ahead of the curve with insights from Peptides Today.

Disclaimer: This information is for research purposes only and not medical advice. Always consult a healthcare provider for medical needs.

#Retatrutide #PeptideTherapeutics #WeightLossResearch #DiabetesResearch #EliLilly